Biotech, acquisitions, Biogen Idec
Biogen Idec Sets Date for Showdown With Icahn, Proxy Battle Begins
Robert Buderi 5/9/08
The meeting date has been set, the battle lines drawn, proxy salvos lobbed. And one famous Biogen Idec board member goes unnamed.
That’s the latest in the struggle between Biogen Idec and Carl Icahn. Yesterday, at long last, Biogen (NASDAQ: BIIB) set June 19 as the date for its annual meeting—where shareholders will chose between separate board slates advanced by the company and the famous activist investor, who has taken a 4.24 percent stake in the biotech and is pushing for its sale. In concert with setting the meeting date, Biogen also filed proxy materials that include a letter to shareholders making its case against Icahn, who in his own letter to investors urges shareholders to vote for current board... Read more »
Share
